Asset Details
Do you wish to reserve the book?
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET
Do you wish to request the book?
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET
2018
Overview
To validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients.
Baseline comorbidity scores collected using the TIBI-CaP were compared with the baseline patient-reported health-related quality of life using the SF-12v2 and FACT-P questionnaires in 302 patients enrolled in the Treatment Registry for Outcomes in CRPC Patients (TRUMPET).
Baseline TIBI-CaP scores were negatively correlated with all baseline SF-12v2 domain/composite (p < 0.001) and FACT-P subscale/total (p < 0.020) scores. There was a significant decreasing linear trend in SF12v2 and FACT-P scores over the categories based on TIBI-CaP quartiles of comorbidity burden (from 'least' to 'severe').
The TIBI-CaP is a valid measure of comorbidity burden in patients with CRPC in the real world.
This study aimed to validate the total illness burden index for prostate cancer (TIBI-CaP), a patient-reported measure of comorbidity burden, in a cohort of men enrolled in the Treatment Registry for Outcomes in Castration-resistant Prostate Cancer (CRPC) Patients (TRUMPET). Results from this study demonstrate that the TIBI-CaP is a valid measure of comorbidity burden in CRPC patients in the real world and a useful research tool for risk adjustment in CRPC studies.
Publisher
Future Medicine Ltd
Subject
/ castration-resistant prostate cancer
/ CRPC
/ Diabetes
/ Humans
/ Male
/ Patients
/ Prostatic Neoplasms, Castration-Resistant - diagnosis
/ Prostatic Neoplasms, Castration-Resistant - epidemiology
/ Prostatic Neoplasms, Castration-Resistant - mortality
/ Prostatic Neoplasms, Castration-Resistant - therapy
/ Studies
/ TIBI-CaP
/ total illness burden index for prostate cancer
/ United States - epidemiology
/ Urology
